Previously, CHRDL2 has been recognized as an oncogenic factor in breast cancer, lung cancer, colon cancer, and osteosarcoma, with elevated levels in tissue samples and promoting tumorigenesis [[29], [30], [31]]. This evidence concerns the gene CHRDL2 and osteosarcoma.